domperidone has been researched along with Black Fever in 4 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse drug reactions were reported." | 3.30 | A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard ( Baxarias, M; Donato, G; Homedes, J; Mateu, C; Miró, G; Pennisi, MG; Salichs, M; Solano-Gallego, L, 2023) |
| "Domperidone is a dopamine D2 receptor antagonist that has shown to enhance the innate cell-mediated immune response." | 2.79 | A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area. ( Ferrer, L; Homedes, J; Llinás, J; Sabaté, D; Sust, M, 2014) |
| "Domperidone was effective in controlling and reducing clinical signs and antibody titre." | 2.74 | Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial. ( Alvarez, F; Castillo, JA; Couto, CG; Gascón, M; Gómez-Ochoa, P; Zarate, JJ, 2009) |
| "Domperidone treatment has shown to prevent overt disease or improve the clinical condition of infected dogs." | 1.48 | Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. ( Miró, G; Travi, BL, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baxarias, M | 1 |
| Donato, G | 1 |
| Mateu, C | 1 |
| Salichs, M | 1 |
| Homedes, J | 2 |
| Miró, G | 2 |
| Pennisi, MG | 1 |
| Solano-Gallego, L | 1 |
| Travi, BL | 1 |
| Sabaté, D | 1 |
| Llinás, J | 1 |
| Sust, M | 1 |
| Ferrer, L | 1 |
| Gómez-Ochoa, P | 1 |
| Castillo, JA | 1 |
| Gascón, M | 1 |
| Zarate, JJ | 1 |
| Alvarez, F | 1 |
| Couto, CG | 1 |
3 trials available for domperidone and Black Fever
| Article | Year |
|---|---|
A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard
Topics: Animals; Antibodies, Protozoan; Dog Diseases; Dogs; Domperidone; Immunotherapy; Leishmania infantum; | 2023 |
A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area.
Topics: Administration, Oral; Animals; Dog Diseases; Dogs; Domperidone; Dopamine D2 Receptor Antagonists; Im | 2014 |
Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Domperidone; Dopamine Anta | 2009 |
1 other study available for domperidone and Black Fever
| Article | Year |
|---|---|
Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications.
Topics: Animals; Dog Diseases; Dogs; Domperidone; Dopamine Antagonists; Leishmania infantum; Leishmaniasis, | 2018 |